Claims for Patent: 9,694,025

Summary for Patent: 9,694,025

Title:	Cyclic boronic acid ester derivatives and therapeutic uses thereof
Abstract:	Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
Inventor(s):	Hirst; Gavin (San Diego, CA), Reddy; Raja (San Diego, CA), Hecker; Scott (Del Mar, CA), Totrov; Maxim (San Diego, CA), Griffith; David C. (San Marcos, CA), Rodny; Olga (Mill Valley, CA), Dudley; Michael N. (San Diego, CA), Boyer; Serge (San Diego, CA)
Assignee:	Rempex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	15/015,002
Patent Claims:	1. A method of treating a bacterial infection comprising administering to a subject in need thereof an effective amount of a compound having the structure of formula (I): ##STR00210## or a pharmaceutically acceptable salt thereof, wherein: Y is a 1-4 atom alkylene or 2-4 atom alkenylene linker, optionally substituted by one or more substituents selected from the group consisting of Cl, F, CN, CF.sub.3, --R.sup.9, --OR.sup.9, --C(.dbd.O)NR.sup.9R.sup.10, and --C(.dbd.O)OR.sup.9; R.sup.1 is selected from a group consisting of --C.sub.1-9alkyl, --C.sub.2-9alkenyl, --C.sub.2-9alkynyl, --NR.sup.9R.sup.10, --C.sub.1-9alkylR.sup.11, --C.sub.2-9alkenylR.sup.11, --C.sub.2-9alkynylR.sup.11, -carbocyclyl-R.sup.11, --CH(OH)C.sub.1-9alkylR.sup.9, --CH(OH)C.sub.2-9alkenylR.sup.9, --CH(OH)C.sub.2-9alkynylR.sup.9, --CH(OH)carbocyclyl-R.sup.9, --C(.dbd.O)R.sup.9, --C(.dbd.O)C.sub.1-9alkylR.sup.9, --C(.dbd.O)C.sub.2-9alkenylR.sup.9, --C(.dbd.O)C.sub.2-9alkynylR.sup.9, --C(.dbd.O)C.sub.2-9carbocyclyl-R.sup.9, --C(.dbd.O)NR.sup.9R.sup.10, --N(R.sup.9)C(.dbd.O)R.sup.9, --N(R.sup.9)C(.dbd.O)NR.sup.9R.sup.10, --N(R.sup.9)C(.dbd.O)OR.sup.9, --N(R.sup.9)C(.dbd.O)C(.dbd.NR.sup.10)R.sup.9, --N(R.sup.9)C(.dbd.O)C(.dbd.CR.sup.9R.sup.10)R.sup.9, --N(R.sup.9)C(.dbd.O)C.sub.1-4alkylN(R.sup.9)C(.dbd.O)R.sup.9, --N(R.sup.9)C(.dbd.NR.sup.10)R.sup.9, --C(.dbd.NR.sup.10)NR.sup.9R.sup.10, --N.dbd.C(R.sup.9)NR.sup.9R.sup.10, --N(R.sup.9)SO.sub.2R.sup.9, --N(R.sup.9)SO.sub.2NR.sup.9R.sup.10, --N.dbd.CHR.sup.9, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl; R.sup.6 is selected from a group consisting of H, --C.sub.1-9alkyl, C.sub.2-9alkenyl, --C.sub.2-9alkynyl, carbocyclyl, --C.sub.1-9alkylR.sup.11, --C.sub.2-9alkenylR.sup.11, --C.sub.2-9alkynylR.sup.11, carbocyclyl-R.sup.11, --C(.dbd.O)OR.sup.9, --C.sub.1-9alkylCO.sub.2R.sup.9, --C.sub.2-9alkenylCO.sub.2R.sup.9, --C.sub.2-9alkynylCO.sub.2R.sup.9, and -carbocyclyl-CO.sub.2R.sup.9, or alternatively: (i) R.sup.6 and an R.sup.7 are taken together with the atoms to which they are attached to form a substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, or (ii) R.sup.6 is absent when the carbon to which it is attached is a ring atom in an aryl or heteroaryl ring; each R.sup.7 is independently selected from a group consisting of H, halo, --C.sub.1-9alkyl, --C.sub.2-9alkenyl, --C.sub.2-9alkynyl, --NR.sup.9R.sup.10, --OR.sup.9, --C.sub.1-9alkylCO.sub.2R.sup.9, --C.sub.2-9alkenylCO.sub.2R.sup.9, --C.sub.2-9alkynylCO.sub.2R.sup.9, and -carbocyclyl-CO.sub.2R.sup.9, or independently: (i) R.sup.6 and an R.sup.7 are taken together with the atoms to which they are attached to form a substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, or (ii) R.sup.7 and an R.sup.8 are taken together with the atoms to which they are attached to form a substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; each R.sup.8 is independently selected from a group consisting of H, halo, --C.sub.1-9alkyl, --C.sub.2-9alkenyl, --C.sub.2-9alkynyl, --NR.sup.9R.sup.10, --OR.sup.9, --C.sub.1-9alkylCO.sub.2R.sup.9, --C.sub.2-9alkenylCO.sub.2R.sup.9, --C.sub.2-9alkynylCO.sub.2R.sup.9, -carbocyclyl-CO.sub.2R.sup.9, or independently: (i) an R.sup.7 and an R.sup.8 are taken together with the atoms to which they are attached to form a substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl, (ii) a geminal R.sup.7 and R.sup.8 together form --C.sub.2-9alkenylenylCO.sub.2R.sup.9, or (iii) each R.sup.8 attached to a ring atom forming part of a substituted or unsubstituted aryl is absent; each R.sup.9 is independently selected from a group consisting of H, --C.sub.1-9alkyl, C.sub.2-9alkenyl, --C.sub.2-9alkynyl, carbocyclyl, --C.sub.1-9alkylR.sup.11, --C.sub.2-9alkenylR.sup.11, --C.sub.2-9alkynylR.sup.11, -carbocyclyl-R.sup.11, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl; each R.sup.10 is independently selected from a group consisting of H, --C.sub.1-9alkyl, --OR.sup.9, --CH(.dbd.NH), --C(.dbd.O)OR.sup.9, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl; each R.sup.11 is independently selected from a group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbocyclyl, and substituted or unsubstituted heterocyclyl; X is selected from a group consisting of --CO.sub.2R.sup.12, and carboxylic acid isosteres; R.sup.12 is selected from a group consisting of H, C.sub.1-9alkyl, --(CH.sub.2).sub.0-3--R.sub.11, --C(R.sup.13).sub.2OC(O)C.sub.1-9alkyl, --C(R.sup.13).sub.2OC(O)R.sup.11, --C(R.sup.13).sub.2OC(O)OC.sub.1-9alkyl and --C(R.sup.13).sub.2OC(O)OR.sup.11; each R.sup.13 is independently selected from a group consisting of H and C.sub.1-4alkyl; and m is independently zero or an integer from 1 to 2, wherein each C.sub.1-9alkyl, C.sub.2-9alkenyl, and C.sub.2-9alkynyl is independently optionally substituted. 2. The method claim 1, wherein R.sup.6 and each R.sup.7 and R.sup.8 is hydrogen. 3. The method of claim 2, wherein m is 1. 4. The method of claim 3, wherein R.sup.1 is --NHC(.dbd.O)C.sub.1-9alkylR.sup.11. 5. The method of claim 4, wherein R.sup.11is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl. 6. The method of claim 5, wherein R.sup.11is thien-2-yl. 7. The method of claim 1, wherein X is --CO.sub.2H. 8. The method of claim 1, wherein the compound is selected from the group consisting of: ##STR00211## ##STR00212## ##STR00213## ##STR00214## ##STR00215## ##STR00216## ##STR00217## ##STR00218## ##STR00219## ##STR00220## ##STR00221## ##STR00222## ##STR00223## ##STR00224## ##STR00225## ##STR00226## or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein the subject is a mammal. 10. The method of claim 1, wherein the bacterial infection comprises a bacteria selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Burkholderia cepacia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Kingella, Moraxella, Gardnerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group,Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtherias, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus. 11. The method of claim 1, wherein the bacterial infection comprises a bacteria selected from the group consisting of Pseudomonas aeruginosa, Pseudomonas fluorescens, Stenotrophomonas maltophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella, Bacteroides fragilis, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, and Bacteroides splanchnicus. 12. The method of claim 1, wherein the compound is administered orally to the subject. 13. The method of claim 1, wherein the compound is administered intravenously to the subject. 14. The method of claim 1, wherein the compound is: ##STR00227## or a pharmaceutically acceptable salt thereof.